1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow SCCHN: new trials by email Literature Review of SCCHN trials Research Report on SCCHN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection) - Head and Neck Cancers- Squamous Cell, Head and Neck Cancer | Phase 1 | Recruiting | VLP Therapeutics | 41 | 2025-05-13 | 2026-09-21 |
Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Mouth Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Carcinoma (1) · Mouth Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Squamous Cell (1) · Stomatognathic Diseases (1)
pembrolizumab (1)
VLP Therapeutics (1)
United States (1)
Fred M Baik, MD (1)